U.S. Status. The Corporation meets the general eligibility requirements for the use of Form F-10 under the U.S. Securities Act and at the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Corporation or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the U.S. Securities Act) of the Offered Shares and at the date hereof, the Corporation was not and is not an “ineligible issuer”, as defined in Rule 405 under the U.S. Securities Act;
U.S. Status. The Corporation meets the general eligibility requirements for the use of Form F-10 under the U.S. Securities Act; from the time of initial submission of the Registration Statement to the SEC (or, if earlier, the first date on which the Corporation engaged directly or through any person authorized on its behalf in any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the U.S. Securities Act) through the date hereof, the Corporation has been and is an “emerging growth company,” as defined in Section 2(a) of the U.S. Securities Act (an “Emerging Growth Company”); and at the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Corporation or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the U.S. Securities Act) of the Offered Shares and at the date hereof, the Corporation was not and is not an “ineligible issuer”, as defined in Rule 405 under the U.S. Securities Act;
U.S. Status. The Corporation meets the general eligibility requirements for the use of Form F-10 under the U.S. Securities Act; from the time of initial submission of the Registration Statement to the SEC through the date hereof, the Corporation has been and is an “emerging growth company,” as defined in Section 2(a) of the U.S. Securities Act (an “Emerging Growth Company”); and at the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Corporation or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the U.S. Securities Act) of the Offered Shares and at the date hereof, the Corporation was not and is not an “ineligible issuer”, as defined in Rule 405 under the U.S. Securities Act;
U.S. Status. The Contracting Party has consulted the Commodity Exchange Act (United States) and the regulations of the Commodity Futures Trading Commission and to the extent required by U.S. law, the Contracting Party is an (i) "eligible swap participant", (ii) "eligible contract participant" and (iii) "eligible commercial entity" with respect to each Transaction.any swap submitted to NGX.
U.S. Status. The Company is a “foreign private issuer” as defined in Rule 3b-4 under the Exchange Act. The Company is neither an “Accelerated Filer” nor a “Large Accelerated Filer”, as such terms are defined in Rule 12b-2 of the Exchange Act.
U.S. Status. With respect to Notes issued by AstraZeneca Finance LLC (other than for the avoidance of doubt, CMU Notes), the Principal Paying Agent (A) represents (i) that it is the sole paying agent for such Notes and (ii) that it is a "qualified intermediary" within the meaning of U.S. Treasury Regulations Section 1.1441- 1(e)(5)(ii), will remain so, and will assume primary chapter 3 and chapter 4 withholding and 1099 reporting and (B) agrees that upon its appointment it will provide the Issuers with a properly completed, signed and valid IRS Form W- 8IMY, with its Global Intermediary Identification Number included thereon and identifying itself as a qualified intermediary that has undertaken primary responsibility for chapter 3 and chapter 4 withholding and 1099 reporting.
U.S. Status. No Shareholder or Holdco is a “foreign person” within the meaning of Section 1445 of the Code or a Person whose separate existence from a “foreign person” within the meaning of Section 1445 of the Code is disregarded for U.S. federal income Tax purposes.
U.S. Status. THE LENDER IS A U.S. PERSON AS THAT TERM IS DEFINED IN THE UNITED STATES INTERNAL REVENUE CODE. IT IS HEREBY AGREED AND UNDERSTOOD THAT THE OBLIGATIONS HEREUNDER MAY BE SOLD OR RESOLD ONLY TO NON-U.S. PERSONS. THE INTEREST PAYABLE HEREUNDER IS PAYABLE ONLY OUTSIDE THE UNITED STATES. ANY U.S. PERSON WHO HOLDS THIS OBLIGATION WILL BE SUBJECT TO LIMITATIONS UNDER THE UNITED STATES INCOME TAX LAW.
U.S. Status. The Company is a “foreign private issuer” as defined in Rule 3b-4 under the Exchange Act. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Shares and at the date hereof, the Company was not and is not an “ineligible issuer”, as defined in Rule 405 under the Securities Act. The Company neither an “Accelerated Filer” nor a “Large Accelerated Filer”, as such terms are defined in Rule 12b-2 of the Exchange Act.
U.S. Status. The Prostiva RF Therapy system is considered a Class II medical device and meets the premarket notification requirements under section 510(k) of the US FD&C Act. Table 2 lists the Prostiva RF Therapy system models and the corresponding 510k submission that obtained clearance for the currently marketed product. Table 2: Approval Status in the Unites Stales Current Model Clearing 501K Comments 8929 K101139 [* * *] 60883 K052413 [* * *] 8924 K052413 [* * *] 8930 K052413 [* * *] 6101 K002583 [* * *] 8099 / 8099TU15 K002583 [* * *] Medtronic Neuromodulation Confidential Document Number Ver/Rev 2.0 Page 5 of 15 Title: Regulatory Plan - Prostiva® RF Therapy System Transfer to Urologix
